Специфические ингибиторы циклооксигеназы-2 и остеоартроз
Литература
1. Дзяк Г.В. Нестероидные противовоспалительные препараты. Киев, Морион,1999, 111 с.
2. Коваленко В.М. Стан ревматології в Україні: медико-соціальні аспекти та напрямки подальшого розвитку. Ревматологічний журнал, 2002, 2 (8), 3-8.
3. Насонов Е.Л. Целебрекс - доказанная эффективность и безопасность (новые данные). Терапевт. Архив, 2001, 5, 2-5.
4. Насонов Е.Л., Каратеев А.Е. Поражения желудка, связанные с приемом нестероидных противовоспалительных препаратов (часть 1). Рос. Журн. Гастроэнтерологии, гепатологии, колопроктологии, 2002, 3, 4-10.
5. Насонов Е.Л., Каратеев А.Е. Поражения желудка, связанные с приемом нестероидных противовоспалительных препаратов (часть 2). Рос. Журн. Гастроэнтерологии, гепатологии, колопроктологии, 2002, 4, 4-9.
6. Свинцицкий А.С., Пузанова О.Г. Гастродуоденальные осложнения противовоспалительной терапии в ревматологической практике. Ревматологічний журнал, 2002, 2 (8), 15-23.
7. Яблучанский Н.И. Оптимальное ведение соматических больных (общий подход). Основа, 1995.
8. Armstrong C.P., Blower A.L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut, 1987,28, 527-532.
9. Badley E.M., Wang P.P. Arthritis and the aging population: projections of arthritis prevalence in Canada 1991 to 2031. J Rheumatol, 1998, 25(1), 138-144.
10. Bensen W.G., Fiechtner J.J., McMillen J.I., et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc, 1999, 74, 1095-1105.
11. Boers M. NSAIDs and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet, 2001, 357, 1222-1223.
12. Bombardier C., Laine L., Reicin A. at al. , for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med, 2000, 343, 1520-1528.
13. Catella L.F., McAdam B., Morrison B.W. at l. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther, 1999, 289, 735-741.
14. Cheng H.F., Wang J.L., Zhang M.Z. at al. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest, 1999, 103, 953-961.
15. Chrischilles E.A., Wallace R.B. Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population. J Gerontol, 1993, 48, M91-M96.
16. Crofford L.J., Lipsky P.E., Brooks P. at al. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum, 2000, 43:4-13.
17. Eccles M., Freemantle N., Mason J. for the North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group. North of England Evidence Based Guideline Development Project: summary guideline for non-steroidal antiinflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis.
18. Emery P., Zeidler H., Kvien T.K., et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lance, 1999, 354, 2106-2111.
19. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med, 2001, 345, 433-442.
20. Fries J.F. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol, 1991, 18(Suppl 28), 6-10.
21. Frishman W.H. Effects of Nonsteroidal Anti-Inflammatory Drug Therapy on Blood Pressure and Peripheral Edema. Am J Cardiol, 2002, 89(suppl),18D-25D.
22. Garell S., Matarese R.A. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine (Baltimore), 1984, 63, 165-181.
23. Goldstein J.L., Silverstein F.E., Agrawal N.M. et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol, 2000, 95, 1681-1690.
24. Green K., Drvota V., Vesterqvist O. Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins, 1989, 37, 311-315.
25. Griffin M.R. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury [With Discussion]. Am J Med, 1998, 104(3A), 23s-9s, 41s-2s.
26. Harding P., Carretero O.A., Beierwaltes W.H. Chronic cyclooxygenase-2 inhibition blunts low sodium-stimulated renin without changing renal haemodynamics. J Hypertens, 2000, 18, 1107-1113.
27. Harris R.C., Breyer M.D. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol, 2001, 281, F1-F11.
28. Henry D., Lim L.L., Garcia R.L. et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ, 1996, 312, 1563-1566.
29. Hochberg M.C., Altman R.D., Brandt K.D. At Al. Guidelines For The Medical Management Of Osteoarthritis. Arthritis & Rheumatism, 1995, Vol. 38, N11, 1535-1540.
30. Holzer S.S., Cuerdon T. Development of an economic model comparing acetaminophen to NSAIDs in the treatment of mildto-moderate osteoarthritis. Am J Managed Care, 1996, 2 Suppl, 515-526.
31. Imaoka S., Funae Y. The physiological role of P450-derived arachidonic acid metabolites. Nippon Yakurigaku Zasshi, 1998, 112:23-31.
32. Komhoff M., Grone H.-J., Klein T. at al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol, 1997, 272, F460-8.
33. Larsson S.-E., Jonsson B., Palmefors L. Joint disorders and walking disability in Sweden by the year 2000: epidemiologic studies of a Swedish community. Acta Orthop Scand, 1991, 62(Suppl 241), 6-9.
34. Lawrence R.C., Helmick C.G., Arnett F.C. et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum, 1998, 41, 778-799.
35. Leonard J., Rodriguez J.J., Mellen Ph. at al. Cardiovascular events in elderly hypertensive patients with osteoarthritis treated with cox-2 specific inhibitors: insights from the success vi and vii trials. Am J Hypertension, 2002, v. 15, N4, p. 2, p. 120A.
36. Macdonald T.M., Morant S.V., Robinson G.C. et al. Association of upper gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ, 1997, 315, 1333-1337.
37. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001, 286, 954-959.
38. NDA 21-042: VIOXX™ Tablets, NDA 21-052: VIOXX™ Oral Suspension (Rofecoxib) VIOXX™ Gastrointestinal Outcomes Research Study (VIGOR). FDA Advisory Committee Background Information Presented to: Arthritis Advisory Committee February 8, 2001, 144 p.
39. Patrignani P., Sciulli M.G., Manarini S. at al. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999, 50(4), 661-667.
40. Pincus T., Swearingen C., Cummins P. at al. Preference for nonsteroidal anti-inflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol, 2000, 27, 1020-1027.
41. Raskin J.B., White R.H., Jackson J.E. et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med, 1995, 123, 344-350.
42. Ray W.A., Stein C.M., Daugherty J.R. at al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet, 2002, 360, 1071-1073.
43. Ryan J.R., Vargas R., Clay G.A. Role of misoprostol in reducing aspirin-induced gastrointestinal blood loss in arthritic patients. Am J Med, 1987, 83(Suppl 1A), 41-44.
44. Silverstein FE. Improving the gastrointestinal safety of NSAIDs: the development of misoprostol-from hypothesis to clinical practice. Dig Dis Sci, 1998, 43(3), 447-458.
45. Silverstein F.E., Faich G., Goldstein J.L. at al. Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis.The CLASS Study: A Randomized Controlled Trial JAMA, 2000, 284, 1247-1255.
46. Simon L.S., Weaver A.L., Graham D.Y. et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA, 1999, 282, 1921-1928.
47. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Am J Ther, 2000, 7, 121.
48. Singh G., Rosen R.D. NSAID-induced gastrointestinal complications: the ARAMIS perspective-1997: Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl, 1998, 51, 8-16.
49. Swan S.K., Rudy D.W., Lasseter K.C. at al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med, 2000, 133, 1-9.
50. Van Hecken A., Schwartz J.I., Depre M. at al. Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen and Naproxen on COX-2 versus COX-1 in Healthy Volunteers. J Clin Pharmacol, 2000, 40, 1109-1120.
51. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nature New Biology, 1971, 231, 232-235.
52. Wayne E.R. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. The Lancet, 2002, v. 359, 119-123.
53. Wang J.L., Cheng H.F., Harris R.C. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension, 1999, 34, 96-101.
54. Whelton A., Fort J.G., Puma J.A. at al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther , 2001, 8, 85-96.
55. White W.B., Faich G., Whelton A. at al. Comparison of Thromboembolic Events in Patients Treated With Celecoxib, a Cyclooxygenase-2 Specific Inhibitor, Versus Ibuprofen or Diclofenac. Am J Cardiol, 2002, 89, 425-430.
56. White W.B., Kent J., Taylor A. at al. Effects of Celecoxib on Ambulatory Blood Pressure in Hypertensive Patients on ACE Inhibitors. Нypertension. 2002;39:929-934.
57. Wolfe F., Zhao S., Lane N. Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum, 2000, 43, 378-385.
58. Yeomans N.E., Tulassay Z., Juhasz L. et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med, 1998, 338, 719-726.
Ваш комментарий